The estimated Net Worth of Andrea Acosta is at least $15 Milión dollars as of 27 August 2024. Ms. Acosta owns over 3,845 units of Biomarin Pharmaceutical stock worth over $14,640,404 and over the last 4 years she sold BMRN stock worth over $405,562. In addition, she makes $0 as Chief Accounting Officer a Group Vice President at Biomarin Pharmaceutical.
Andrea has made over 3 trades of the Biomarin Pharmaceutical stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 3,845 units of BMRN stock worth $121,387 on 27 August 2024.
The largest trade she's ever made was selling 3,845 units of Biomarin Pharmaceutical stock on 27 August 2024 worth over $121,387. On average, Andrea trades about 466 units every 3 days since 2020. As of 27 August 2024 she still owns at least 172,687 units of Biomarin Pharmaceutical stock.
You can see the complete history of Ms. Acosta stock trades at the bottom of the page.
Andrea Acosta has been appointed as Chief Accounting Officer, Group Vice President of the Company effective 7/13/2020. Ms. Acosta joined BioMarin in 2017 as Vice President, Corporate Controller. Prior to BioMarin, Ms. Acosta worked at Levi Strauss & Co. as Vice President, Global Controller and Principal Accounting Officer where she had various roles of increasing responsibility in finance management during her tenure. Previously, she worked at KPMG LLP as a manager in the firm's audit practice. She earned a BS in Accounting at San Francisco State University and is a Certified Public Accountant.
Andrea Acosta is 41, she's been the Chief Accounting Officer a Group Vice President of Biomarin Pharmaceutical since 2020. There are 22 older and no younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
Andrea's mailing address filed with the SEC is C/O PINTEREST, INC., 651 BRANNAN STREET, SAN FRANCISCO, CA, 94107.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy a Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: